Skip to main content
Sweden
Global Fin Swe Nor Den Ger Cze Svk Pol Hun Nld Bel (nl) Bel (fr) USA
  • Aidian – Your aid in diagnostics
  • Produkter
  • Om oss
  • Nyheter
  • Instrument service
  • Antimikrobiell resistens
  • Aidian Academy
  • Mässor & utställningar
  • Våra kunder berättar
Kontakt Sök
Logo
Kontakt
  • Patientnära diagnostik
  • Mikrobiologi
  • Molekylär mikrobiologi
  • Hygienkontroll
  • RIA / Kollagener
  • Luftvägsinfektioner
  • Andra
Patientnära diagnostik
  • QuikRead go-systemet
  • QuikRead 101
  • Nova Biomedical
  • SD BIOSENSOR STANDARD F
  • bioLytical Laboratories INSTI®
  • ACRO™ Biotech
  • microINR
  • Certest
  • Actim
  • Hangzhou AllTest Biotech
Läs mer
QuikRead go
  • QuikRead go Plus Instrument
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go CRP
  • QuikRead go CRP+Hb
  • QuikRead go wrCRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go Strep A
  • QuikRead go iFOBT
  • QuikRead go tillbehör
QuikRead go
Mikrobiologi
  • Uricult
  • Uricult Vet
  • Cultura M
  • Reagena
  • MIKROGEN serologi
  • Meridian Immunoassays
  • Meridian Curian®
Läs mer
Molekylär mikrobiologi
  • Meridian Revogene®
  • Meridian Alethia®
  • MIKROGEN molecular diagnostics
  • SD BIOSENSOR STANDARD M10
Läs mer
Hygienkontroll
  • Easicult
  • Hygicult
  • Clean Card PRO
Läs mer
RIA / Kollagener
  • UniQ RIA
Läs mer
Andra
  • Grifols Promonitor®
Läs mer
  • Aidian i Sverige
  • Styrelse och ledning
  • Hållbarhet
  • Kultur
  • Karriär hos Aidian
  • Nyheter
  • Produktnyheter
  • AMR
  • Möten
  • Stories from customers
  • COVID-19
  • QuikRead go -serviceorder
  • Vanliga frågor och svar
  • Kontaktinformation
  • Om C-reaktivt protein (CRP)
  • CRP och nedre luftvägsinfektioner
  • Material
  • QuikRead go CRP-produkter
  • Spridning av antibiotikaresistenta bakterier
  • Användbara länkar
  • Allmänt
  • Produktinformation
  • Kurser
  • Dokument och material
  • Vanliga frågor
  • Sovhygien: övervakning av renheten hos kuddar och sängkläder
  • Nya instrument ger patienter rätt vård - på plats direkt
Logo
Kontakt Stäng
  • Produkter
    • Patientnära diagnostik
      • QuikRead go-systemet
      • QuikRead 101
      • Nova Biomedical
      • SD BIOSENSOR STANDARD F
      • bioLytical Laboratories INSTI®
      • ACRO™ Biotech
      • microINR
      • Certest
      • Actim
      • Hangzhou AllTest Biotech
    • Mikrobiologi
      • Uricult
      • Uricult Vet
      • Cultura M
      • Reagena
      • MIKROGEN serologi
      • Meridian Immunoassays
      • Meridian Curian®
    • Molekylär mikrobiologi
      • Meridian Revogene®
      • Meridian Alethia®
      • MIKROGEN molecular diagnostics
      • SD BIOSENSOR STANDARD M10
    • Hygienkontroll
      • Easicult
      • Hygicult
      • Clean Card PRO
    • RIA / Kollagener
      • UniQ RIA
    • Luftvägsinfektioner
    • Andra
      • Grifols Promonitor®
  • Om oss
    • Aidian i Sverige
    • Styrelse och ledning
    • Hållbarhet
    • Kultur
    • Karriär hos Aidian
  • Nyheter
    • Nyheter
    • Produktnyheter
    • AMR
    • Möten
    • Stories from customers
    • COVID-19
  • Instrument service
    • QuikRead go -serviceorder
    • Vanliga frågor och svar
    • Kontaktinformation
  • Antimikrobiell resistens
    • Om C-reaktivt protein (CRP)
    • CRP och nedre luftvägsinfektioner
    • Material
    • QuikRead go CRP-produkter
    • Spridning av antibiotikaresistenta bakterier
    • Användbara länkar
  • Aidian Academy
    • Allmänt
    • Produktinformation
    • Kurser
    • Dokument och material
    • Vanliga frågor
  • Mässor & utställningar
  • Våra kunder berättar
    • Sovhygien: övervakning av renheten hos kuddar och sängkläder
    • Nya instrument ger patienter rätt vård - på plats direkt
Populära produkter
AllTest hCG snabbtest

AllTest hCG snabbtest

AllTest MONO snabbtest

AllTest MONO snabbtest

Acro Strep A rapid test

Acro Strep A rapid test

Senaste nyheter
Visa alla

Introduktion av QuikRead go Plus Instrument!

20 januari 2025 | Nyheter, Produktnyheter

Increase in influenza and RSV activity in the EU/EEA

14 januari 2025 | Nyheter

Webinar: A Point-of-Care analyzer for DOAC testing

25 november 2024 | Möten

  • Visa alla
  • Inga resultat
  • Loading...
Nyheter

Introduktion av QuikRead go Plus Instrument!

20 januari 2025 | Nyheter, Produktnyheter

Increase in influenza and RSV activity in the EU/EEA

14 januari 2025 | Nyheter

Tillbaka till alla nyheter
29 november 2023
Nyheter,
Produktnyheter

Benefits of Bladder EpiCheck for bladder cancer surveillance

As November, Bladder Health Month 2023, is coming to an end we want to highlight Bladder Cancer surveillance.

Bladder cancer is the 5th most common cancer in Europe, affecting over 200 000 people yearly.1 Non-muscle-invasive bladder cancer (NMIBC) accounts for the majority of newly diagnosed bladder cancers. With up to 70% of patients experiencing recurrence within 2 years of initial treatment and 10-15% progressing to higher risk cancer, monitoring of bladder cancer is vital.2

The current gold standard methods for bladder cancer surveillance are cystoscopy and cytology. However, they have their limitations as both are based on operator-dependent assessment. Cytology has low to moderate sensitivity, while some types of tumours are easily missed in cystoscopy.2

During the first years after initial treatment, bladder cancer patients undergo as many as 4 cystoscopies a year. Cystoscopy is an invasive and expensive procedure, so the need for an effective biomarker test for surveillance is high.

Bladder EpiCheck® from Nucleix is a urine marker test for monitoring of NMIBC. It uses a panel of 15 DNA methylation markers and is included in the EAU (European Association of Urology) guidelines for bladder cancer surveillance. The guidelines state that Bladder EpiCheck could be used to replace and/or postpone cystoscopy.3

Bladder EpiCheck

A meta-analysis of the diagnostic accuracy of urinary biomarker tests found that Bladder EpiCheck has a high-grade Negative Predictive Value (NPV) of 99 %, high-grade sensitivity of 91 % and specificity of 84 %.4

The results of the test are objective and not affected by BCG treatment, hematuria, or infections.5 The high performance of the test makes it a reliable tool to rule out high-risk recurrence and reduce unnecessary procedures.

Reducing the number of cystoscopies by incorporating Bladder EpiCheck into the surveillance of bladder cancer could lessen the strain on the healthcare system as well as benefit the well-being of patients.

For more detailed information about Bladder EpiCheck, head to the Bladder EpiCheck product site or contact us.

Aidian is the proud distributor of Bladder EpiCheck in the Nordics.


References

  1. European Association of Urology. Bladder Cancer: The Forgotten Cancer. https://uroweb.org/news/bladder-cancer-the-forgotten-cancer. Accessed 27.11.2023.
  2. Biomarkers in the management of non-muscle invasive bladder cancer (NMIBC), BCaMonitor, Updated May 2023.
  3. EAU Non-muscle-invasive Bladder Cancer guidelines 2022. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/diagnosis
  4. Laukhtina et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2021 Dec;4(6):927-942; and corrigendum at Eur Urol Oncol. 2022 Jan 19;S2588-9311(22)00004-9.
  5. Cochetti et al. Urol Onc Nov 2021; Pierconti et al. Urol Onc Nov 2021, Bladder EpiCheck® EU Instructions For Use, 09-May-2022


Share
Facebook
Twitter
E-post

Aidian Sweden AB

Råsta Strand väg 13C
169 79 Solna


08 623 04 00


Förfrågningar
info@aidian.se


Försäljning
order@aidian.se

Företag
  • Om oss
  • Hållbarhet
  • Karriär hos Aidian
  • Kontakt
Produkter
  • Patientnära diagnostik
  • Mikrobiologi
  • Molekylär mikrobiologi
  • Hygienkontroll
  • RIA / Kollagener
  • Luftvägsinfektioner
  • Andra
Snabblänkar
  • Aidian Academy
  • Aidian Connect
  • Instrument service
Copyright © 2025 Aidian
  • Integritetsskyddspolicy
  • Integritetsmeddelande
  • Cookiepolicy
  • Sociala medier policy